Structural and Functional View of Polypharmacology

Protein domains mediate drug-protein interactions and this principle can guide the design of multi-target drugs i.e. polypharmacology. In this study, we associate multi-target drugs with CATH functional families through the overrepresentation of targets of those drugs in CATH functional families. Thus, we identify CATH functional families that are currently enriched in drugs (druggable CATH functional families) and we use the network properties of these druggable protein families to analyse their association with drug side effects. Analysis of selected druggable CATH functional families, enriched in drug targets, show that relatives exhibit highly conserved drug binding sites. Furthermore, relatives within druggable CATH functional families occupy central positions in a human protein functional network, cluster together forming network neighbourhoods and are less likely to be within proteins associated with drug side effects. Our results demonstrate that CATH functional families can be used to identify drug-target interactions, opening a new research direction in target identification.

[1]  Damian Szklarczyk,et al.  The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored , 2010, Nucleic Acids Res..

[2]  Michael J. Keiser,et al.  Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.

[3]  W R Taylor,et al.  Protein structure alignment. , 1989, Journal of molecular biology.

[4]  H. Burris,et al.  Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. , 2004, The oncologist.

[5]  B. Roth,et al.  Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia , 2004, Nature Reviews Drug Discovery.

[6]  Jürgen Bajorath,et al.  Many structurally related drugs bind different targets whereas distinct drugs display significant target overlap , 2012 .

[7]  W R Taylor,et al.  SSAP: sequential structure alignment program for protein structure comparison. , 1996, Methods in enzymology.

[8]  A. Barabasi,et al.  Uncovering disease-disease relationships through the incomplete interactome , 2015, Science.

[9]  James H. Doroshow,et al.  Safety and feasibility of targeted agent combinations in solid tumours , 2013, Nature Reviews Clinical Oncology.

[10]  Benjamin A. Shoemaker,et al.  IBIS (Inferred Biomolecular Interaction Server) reports, predicts and integrates multiple types of conserved interactions for proteins , 2011, Nucleic Acids Res..

[11]  C. Chothia,et al.  Evolution of the Protein Repertoire , 2003, Science.

[12]  K. Shokat,et al.  Targeting the cancer kinome through polypharmacology , 2010, Nature Reviews Cancer.

[13]  John P. Overington,et al.  Mapping small molecule binding data to structural domains , 2012, BMC Bioinformatics.

[14]  E V Koonin,et al.  Estimating the number of protein folds and families from complete genome data. , 2000, Journal of molecular biology.

[15]  Christine A. Orengo,et al.  Protein function prediction using domain families , 2013, BMC Bioinformatics.

[16]  A. Barabasi,et al.  Drug—target network , 2007, Nature Biotechnology.

[17]  Yoshihiro Yamanishi,et al.  Extracting Sets of Chemical Substructures and Protein Domains Governing Drug-Target Interactions , 2011, J. Chem. Inf. Model..

[18]  Sarah A. Teichmann,et al.  An insight into domain combinations , 2001, ISMB.

[19]  J. Bajorath,et al.  Polypharmacology: challenges and opportunities in drug discovery. , 2014, Journal of medicinal chemistry.

[20]  Jordi Mestres,et al.  Polypharmacology in Precision Oncology: Current Applications and Future 
Prospects , 2016, Current pharmaceutical design.

[21]  John M. Barnard,et al.  Chemical Similarity Searching , 1998, J. Chem. Inf. Comput. Sci..

[22]  U. Bhalla,et al.  Functional modules in biological signalling networks. , 2001, Novartis Foundation symposium.

[23]  Christine A. Orengo,et al.  Finding the “Dark Matter” in Human and Yeast Protein Network Prediction and Modelling , 2010, PLoS Comput. Biol..

[24]  John P. Overington,et al.  PPDMs—a resource for mapping small molecule bioactivities from ChEMBL to Pfam-A protein domains , 2014, Bioinform..

[25]  J. A. Ranea,et al.  Exploring the interactions of the RAS family in the human protein network and their potential implications in RAS-directed therapies , 2016, Oncotarget.

[26]  T. Geppert,et al.  Biological Networks and Drug Discovery—Where Do We Stand? , 2014, Drug development research.

[27]  John P. Overington,et al.  Can we rationally design promiscuous drugs? , 2006, Current opinion in structural biology.

[28]  Erli Pang,et al.  Promiscuous domains: facilitating stability of the yeast protein-protein interaction network. , 2012, Molecular bioSystems.

[29]  M. Rask-Andersen,et al.  The druggable genome: Evaluation of drug targets in clinical trials suggests major shifts in molecular class and indication. , 2014, Annual review of pharmacology and toxicology.

[30]  J. Lees,et al.  Defining functional interactions during biogenesis of epithelial junctions , 2016, Nature Communications.

[31]  Peter S. Kutchukian,et al.  Rethinking molecular similarity: comparing compounds on the basis of biological activity. , 2012, ACS chemical biology.

[32]  Juancarlos Chan,et al.  Gene Ontology Consortium: going forward , 2014, Nucleic Acids Res..

[33]  E. Raymond,et al.  Benefit-Risk Assessment of Sunitinib in Gastrointestinal Stromal Tumours and Renal Cancer , 2009, Drug safety.

[34]  A. Barabasi,et al.  Lethality and centrality in protein networks , 2001, Nature.

[35]  Tapio Salakoski,et al.  An expanded evaluation of protein function prediction methods shows an improvement in accuracy , 2016, Genome Biology.

[36]  Péter Csermely,et al.  The efficiency of multi-target drugs: the network approach might help drug design. , 2004, Trends in pharmacological sciences.

[37]  M. Rask-Andersen,et al.  Trends in the exploitation of novel drug targets , 2011, Nature Reviews Drug Discovery.

[38]  R. Iyengar,et al.  Systems pharmacology: network analysis to identify multiscale mechanisms of drug action. , 2012, Annual review of pharmacology and toxicology.

[39]  E. Koonin,et al.  The structure of the protein universe and genome evolution , 2002, Nature.

[40]  Peer Bork,et al.  The SIDER database of drugs and side effects , 2015, Nucleic Acids Res..

[41]  Vincent Le Guilloux,et al.  Fpocket: An open source platform for ligand pocket detection , 2009, BMC Bioinformatics.

[42]  Prudence Mutowo-Meullenet,et al.  The GOA database: Gene Ontology annotation updates for 2015 , 2014, Nucleic Acids Res..

[43]  E. Birney,et al.  Pfam: the protein families database , 2013, Nucleic Acids Res..

[44]  Antonio Lavecchia,et al.  In silico methods to address polypharmacology: current status, applications and future perspectives. , 2016, Drug discovery today.

[45]  Patrick Aloy,et al.  IntSide: a web server for the chemical and biological examination of drug side effects , 2014, Bioinform..

[46]  Haiyuan Yu,et al.  Three-dimensional reconstruction of protein networks provides insight into human genetic disease , 2012, Nature Biotechnology.

[47]  A G Murzin,et al.  SCOP: a structural classification of proteins database for the investigation of sequences and structures. , 1995, Journal of molecular biology.

[48]  Hadley Wickham,et al.  ggplot2 - Elegant Graphics for Data Analysis (2nd Edition) , 2017 .

[49]  Adam Godzik,et al.  Cd-hit: a fast program for clustering and comparing large sets of protein or nucleotide sequences , 2006, Bioinform..

[50]  Haiyuan Yu,et al.  Target Essentiality and Centrality Characterize Drug Side Effects , 2013, PLoS Comput. Biol..

[51]  Peter Dalgaard,et al.  R Development Core Team (2010): R: A language and environment for statistical computing , 2010 .

[52]  John P. Overington,et al.  How many drug targets are there? , 2006, Nature Reviews Drug Discovery.

[53]  Jürgen Bajorath,et al.  Polypharmacology Directed Compound Data Mining: Identification of Promiscuous Chemotypes with Different Activity Profiles and Comparison to Approved Drugs , 2010, J. Chem. Inf. Model..

[54]  Alfonso Valencia,et al.  Integration of biological data by kernels on graph nodes allows prediction of new genes involved in mitotic chromosome condensation , 2014, Molecular biology of the cell.

[55]  E. Berg Systems biology in drug discovery and development. , 2014, Drug discovery today.

[56]  Benoit H. Dessailly,et al.  Functional site plasticity in domain superfamilies☆ , 2013, Biochimica et biophysica acta.

[57]  Miguel Ángel Medina,et al.  Systems biology for molecular life sciences and its impact in biomedicine , 2012, Cellular and Molecular Life Sciences.

[58]  Patrick Aloy,et al.  Analysis of chemical and biological features yields mechanistic insights into drug side effects. , 2013, Chemistry & biology.

[59]  Sarah A. Teichmann,et al.  Protein domain organisation: adding order , 2009, BMC Bioinformatics.

[60]  George Papadatos,et al.  The ChEMBL bioactivity database: an update , 2013, Nucleic Acids Res..

[61]  Aurelio A. Moya-García,et al.  Insights into polypharmacology from drug-domain associations , 2013, Bioinform..

[62]  R. Solé,et al.  Data completeness—the Achilles heel of drug-target networks , 2008, Nature Biotechnology.

[63]  Adam Godzik,et al.  Analysis of Individual Protein Regions Provides Novel Insights on Cancer Pharmacogenomics , 2015, PLoS Comput. Biol..

[64]  I. Morilla,et al.  Oncogenic Signalling Networks and Polypharmacology as Paradigms to Cope with Cancer Heterogeneity , 2014 .

[65]  David A. Lee,et al.  Functional classification of CATH superfamilies: a domain-based approach for protein function annotation , 2015, Bioinform..

[66]  X. Barril,et al.  Understanding and predicting druggability. A high-throughput method for detection of drug binding sites. , 2010, Journal of medicinal chemistry.

[67]  R. Sharan,et al.  Network-based prediction of protein function , 2007, Molecular systems biology.

[68]  Ruth Nussinov,et al.  Structure and dynamics of molecular networks: A novel paradigm of drug discovery. A comprehensive review , 2012, Pharmacology & therapeutics.

[69]  G. Maggiora,et al.  Molecular similarity in medicinal chemistry. , 2014, Journal of medicinal chemistry.

[70]  Dietrich Rebholz-Schuhmann,et al.  The functional therapeutic chemical classification system , 2013, Bioinform..

[71]  Daniel W. A. Buchan,et al.  A large-scale evaluation of computational protein function prediction , 2013, Nature Methods.

[72]  E. Freire,et al.  Finding a better path to drug selectivity. , 2011, Drug discovery today.

[73]  Olaf Wolkenhauer,et al.  Evolution of Centrality Measurements for the Detection of Essential Proteins in Biological Networks , 2016, Front. Physiol..

[74]  A. Hopkins,et al.  The druggable genome , 2002, Nature Reviews Drug Discovery.

[75]  David C. Jones,et al.  CATH--a hierarchic classification of protein domain structures. , 1997, Structure.

[76]  Andrew B. Clegg,et al.  CODA: Accurate Detection of Functional Associations between Proteins in Eukaryotic Genomes Using Domain Fusion , 2010, PloS one.

[77]  E. Blomme,et al.  Potential functional and pathological side effects related to off-target pharmacological activity. , 2017, Journal of pharmacological and toxicological methods.

[78]  Davide Heller,et al.  STRING v10: protein–protein interaction networks, integrated over the tree of life , 2014, Nucleic Acids Res..

[79]  C. Sander,et al.  Automated Network Analysis Identifies Core Pathways in Glioblastoma , 2010, PloS one.

[80]  Aric Hagberg,et al.  Exploring Network Structure, Dynamics, and Function using NetworkX , 2008, Proceedings of the Python in Science Conference.

[81]  Philip M. Kim,et al.  Evolution of biological interaction networks: from models to real data , 2011, Genome Biology.

[82]  Avi Ma'ayan,et al.  Lean Big Data integration in systems biology and systems pharmacology. , 2014, Trends in pharmacological sciences.

[83]  Christine A. Orengo,et al.  Gene3D: merging structure and function for a Thousand genomes , 2009, Nucleic Acids Res..

[84]  David Rogers,et al.  Extended-Connectivity Fingerprints , 2010, J. Chem. Inf. Model..

[85]  A. Hopkins Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.

[86]  David A. Lee,et al.  GeMMA: functional subfamily classification within superfamilies of predicted protein structural domains , 2009, Nucleic acids research.

[87]  Jame Abraham,et al.  Lapatinib in the treatment of breast cancer , 2007, Expert review of anticancer therapy.

[88]  T. Ramsay,et al.  Benefit, Risk, and Outcomes in Drug Development: A Systematic Review of Sunitinib. , 2016, Journal of the National Cancer Institute.

[89]  Jürgen Bajorath,et al.  Rationalizing Structure and Target Relationships between Current Drugs , 2012, The AAPS Journal.

[90]  J. Hopfield,et al.  From molecular to modular cell biology , 1999, Nature.

[91]  C. Myers,et al.  Using networks to measure similarity between genes: association index selection , 2013, Nature Methods.

[92]  Tudor I. Oprea,et al.  A comprehensive map of molecular drug targets , 2016, Nature Reviews Drug Discovery.

[93]  Philip S. Yu,et al.  A new method to measure the semantic similarity of GO terms , 2007, Bioinform..

[94]  Ian Sillitoe,et al.  Gene3D: a domain-based resource for comparative genomics, functional annotation and protein network analysis , 2011, Nucleic Acids Res..

[95]  David A. Lee,et al.  CATH: comprehensive structural and functional annotations for genome sequences , 2014, Nucleic Acids Res..

[96]  S. Lampel,et al.  The druggable genome: an update. , 2005, Drug discovery today.

[97]  E. Smit,et al.  Side-Effects of Long-Term Administration of Erlotinib in Patients with Non-small Cell Lung Cancer , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[98]  Yibo Wu,et al.  GOSemSim: an R package for measuring semantic similarity among GO terms and gene products , 2010, Bioinform..

[99]  Mark Gerstein,et al.  The Importance of Bottlenecks in Protein Networks: Correlation with Gene Essentiality and Expression Dynamics , 2007, PLoS Comput. Biol..

[100]  M. Ashburner,et al.  Gene Ontology: tool for the unification of biology , 2000, Nature Genetics.

[101]  Piet Van Mieghem,et al.  Topology of molecular interaction networks , 2013, BMC Systems Biology.

[102]  Samik Ghosh,et al.  Elucidation of the molecular mechanisms underlying adverse reactions associated with a kinase inhibitor using systems toxicology , 2015, npj Systems Biology and Applications.

[103]  Shuxing Zhang,et al.  Computational polypharmacology: a new paradigm for drug discovery , 2017, Expert opinion on drug discovery.